HIV fusion and its inhibition - PubMed (original) (raw)

Review

HIV fusion and its inhibition

C C LaBranche et al. Antiviral Res. 2001 May.

No abstract available

PubMed Disclaimer

Similar articles

• The potential for HIV fusion inhibition.
  Cammack N. Cammack N. Curr Opin Infect Dis. 2001 Feb;14(1):13-6. doi: 10.1097/00001432-200102000-00003. Curr Opin Infect Dis. 2001. PMID: 11979109 Review.
• Fusion inhibitors: T-20 and T-1249.
  [No authors listed] [No authors listed] TreatmentUpdate. 2001 Spring;12(12):2-3. TreatmentUpdate. 2001. PMID: 11570088 No abstract available.
• Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
  Ketas TJ, Frank I, Klasse PJ, Sullivan BM, Gardner JP, Spenlehauer C, Nesin M, Olson WC, Moore JP, Pope M. Ketas TJ, et al. J Virol. 2003 Feb;77(4):2762-7. doi: 10.1128/jvi.77.4.2762-2767.2003. J Virol. 2003. PMID: 12552019 Free PMC article.
• Resistance to HIV-1 entry inhibitors.
  Olson WC, Maddon PJ. Olson WC, et al. Curr Drug Targets Infect Disord. 2003 Dec;3(4):283-94. doi: 10.2174/1568005033481015. Curr Drug Targets Infect Disord. 2003. PMID: 14754430 Review.
• Katy, bar the door! HIV entry inhibitors.
  Martinez LJ. Martinez LJ. Res Initiat Treat Action. 2000 Jun;6(2):6-12. Res Initiat Treat Action. 2000. PMID: 11707878 No abstract available.

Cited by

• Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.
  Qin Y, Banasik M, Kim S, Penn-Nicholson A, Habte HH, LaBranche C, Montefiori DC, Wang C, Cho MW. Qin Y, et al. Virology. 2014 Aug;462-463:363-76. doi: 10.1016/j.virol.2014.06.006. Virology. 2014. PMID: 25046154 Free PMC article.
• Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity.
  Badani H, Garry RF, Wimley WC. Badani H, et al. Biochim Biophys Acta. 2014 Sep;1838(9):2180-97. doi: 10.1016/j.bbamem.2014.04.015. Epub 2014 Apr 26. Biochim Biophys Acta. 2014. PMID: 24780375 Free PMC article. Review.
• Structural and biochemical insights into the V/I505T mutation found in the EIAV gp45 vaccine strain.
  Du J, Wang X, Ma J, Wang J, Qin Y, Zhu C, Liu F, Shao Y, Zhou J, Qiao W, Liu X. Du J, et al. Retrovirology. 2014 Mar 21;11:26. doi: 10.1186/1742-4690-11-26. Retrovirology. 2014. PMID: 24656154 Free PMC article.
• Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.
  Bhattacharyya S, Singh P, Rathore U, Purwar M, Wagner D, Arendt H, DeStefano J, LaBranche CC, Montefiori DC, Phogat S, Varadarajan R. Bhattacharyya S, et al. J Biol Chem. 2013 Apr 5;288(14):9815-9825. doi: 10.1074/jbc.M112.425959. Epub 2013 Feb 21. J Biol Chem. 2013. PMID: 23430741 Free PMC article.
• Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides.
  Ashkenazi A, Shai Y. Ashkenazi A, et al. Eur Biophys J. 2011 Apr;40(4):349-57. doi: 10.1007/s00249-010-0666-z. Epub 2011 Jan 22. Eur Biophys J. 2011. PMID: 21258789 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information